Drawing for SOCTEC

USPTO serial 86364754

SOCTEC

Reviewed by CopyMark Law Group

Reg. 5494819Status 705Registered
Filing date
Status date
Registration date
Jun 19, 2018
Examiner
HENRY, NAKIA D
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights. Track next renewal deadlines in TSDR and WIPO records.

Status 705: Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights.

Need help with SOCTEC?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Molly Buck Richard

Molly Buck Richard RICHARD LAW GROUP13355 Noel Rd, Suite 1350DALLAS, TX 75240United States

Goods and services

ClassDescriptionStatusFirst use
005[ Pharmaceuticals having a self-orienting effect, namely, orally delivered pharmaceuticals with modified time release into the gastrointestinal system; gastro retentive pharmaceuticals; self orienting pharmaceuticals in the form of capsules, namely, capsules consisting of segments of varied functions and absorption rates, resulting in controlled release into the gastrointestinal tract; Gastrointestinal drug delivery preparations for medical, surgical and biological purposes; chronotherapy-focused tablets, analgesics; Medicines for treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; medicinal preparations for treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; capsules for the release of colonic drug delivery; pharmaceuticals for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders, medical and veterinary preparations for body slimming purposes; capsules, suppositories, tablets and pills for pharmaceutical, medical and veterinary purposes for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; pre-filled vials containing medical diagnostic reagents; exclude goods being related to the treatment of respiratory diseases ]SECTION 8 - CANCELLED—
010[ inhalers for medical purposes; injection apparatus, instruments and devices, namely, medical apparatus in the nature of an infusion injection device for administering drugs; apparatus, instruments and devices, namely, automated drug delivery systems for storing and dispensing medical, surgical and veterinary preparations, capsules, powders, tablets and pills; instruments and apparatus for the administration of self-orientation therapy and prophylaxis preparations and substances, namely, gastrointestinal drug delivery systems, syringes and fluid injectors for medical purposes; exclude goods being related to the treatment of respiratory diseases ]SECTION 8 - CANCELLED—
042Scientific and technological services, namely, custom design exclusively in the pharmaceuticals and medical fields; design services exclusively in the pharmaceuticals and medical fields; drug development and custom design of pharmaceuticals and medical goods; exclude services in the field of inhalation technologyACTIVE—
044[ Medical services; veterinary services; hygienic care for human beings or animals; medical analysis for the diagnosis and treatment of persons treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; pharmacy advice; provision of information relating to medical, surgical and veterinary matters online from a computer database or over the Internet; exclude services in the field of inhalation technology ]SECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 22, 2025NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Jan 22, 2025C15PREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Jan 21, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Aug 29, 2024E815TEAS SECTION 8 & 15 RECEIVED—
Aug 22, 2024ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jun 19, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jun 19, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 29, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 3, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 3, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 14, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 26, 2018PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 13, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 13, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Feb 12, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 12, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 12, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 27, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 27, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 27, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 3, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 3, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 2, 2017ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Oct 31, 2017GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Oct 31, 2017GNSLLETTER OF SUSPENSION E-MAILED—
Oct 31, 2017CNSLSUSPENSION LETTER WRITTEN—
Oct 31, 2017ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Oct 31, 2017OTHECASE RETURNED TO EXAMINATION—
Oct 31, 2017IUCNNOTICE OF ALLOWANCE CANCELLED—
May 9, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 14, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 14, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 22, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 7, 2017PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jan 31, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 31, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Jan 31, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 31, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 31, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 15, 2016GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Aug 15, 2016GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Aug 15, 2016CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jul 20, 2016RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jul 14, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 14, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 14, 2016ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Jan 20, 2016GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jan 20, 2016GNSLLETTER OF SUSPENSION E-MAILED—
Jan 20, 2016CNSLSUSPENSION LETTER WRITTEN—
Dec 29, 2015RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jun 25, 2015GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jun 25, 2015GNSLLETTER OF SUSPENSION E-MAILED—
Jun 25, 2015CNSLSUSPENSION LETTER WRITTEN—
Jun 8, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 8, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 1, 2015ALIEASSIGNED TO LIE—
May 26, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 26, 2014GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 26, 2014GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 26, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 25, 2014DOCKASSIGNED TO EXAMINER—
Aug 21, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 15, 2014NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance